Skip to content

IMPACT OF BHAVANA ON DRUG FORMULATION

IMPACT OF BHAVANA ON DRUG FORMULATION AND ITS EFFECT ON EKA KUSHTHA (PSORIASIS) IN COMPARISON TO VIRECHANA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/01/006546
Enrollment
90
Registered
2016-01-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients having signs and symptoms of Eka Kushtha(Psoriasis)

Interventions

Intervention1: Trial Drug 2 : Brahmi Swarasa bhavita Guduchi Churna (BSBG).: Group B BSBG- 1 gm t.i.d with Luke warm water after meals for 8 week duration. Intervention2: Trial Drug 3 : Guduchi Swaras

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with all forms of Ekakushtha (Psoriasis) who are clinically fit to undergo Virechana Age- 18 to 60 years

Exclusion criteria

Exclusion criteria: Patients who are clinically unfit for Virechana Age 60yrs. Pregnant women Uncontrolled Diabetes Mellitus & Hypertension Any other serious systemic illness Chronicity more than 10 years Patients who are not willing to be included in the study

Design outcomes

Primary

MeasureTime frame
1 Marked improvement in itching and scaling and other clinical features 2 complete remission of psoriatic lesions 3 Non recurrence after the follow up periodTimepoint: 56 days

Secondary

MeasureTime frame
1 Improvement in skin texture 2 Improvement in Dermatological QOLTimepoint: 28 days

Countries

India

Contacts

Public Contactprof PK Prajapati

IPGT and RA

prajapati.pradeep1@gmail.com9428315733

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026